Little Green Pharma sends the first shipment of cannabis flower medications to Australia

Perth, Australia (CU)_ Perth-based medicinal cannabis producer Little Green Pharma Ltd (ASX: LGP) (LGP), a SEED Innovations Ltd (AIM: SEED) investee firm, has sent its first branded cannabis flower medications to Australia from its Denmark plants. The company is expecting three import cargoes before the end of October. SEED owns 3.1 per cent of LGP. LGP has dispatched 50 kg of its Billy Buttons cannabis flower medication, which contains 16 per cent tetrahydrocannabinol (THC) and will be offered in 15-gram packets. LGP reported that two additional Australian imports of cannabis flower medications from the Danish firm are expected by the end of October.

According to LGP managing director Fleta Solomon, it was a watershed moment. He appreciated the company for its great accomplishment. Solomon expressed pride over the latest accomplishment. He said, “To be able to meet all the regulatory requirements to supply and import product within this timeframe is a significant achievement and consistent with our reputation as a leading global medicinal cannabis business”.

He also explained how flower medicines are gaining popularity in Australia. He said, “Flower medicines are becoming increasingly popular with Australian doctors in prescribing to patients for quick onset of effects, mainly for breakthrough pain or to assist with sleep, and with access to this Denmark-grown product we are able to provide a new supply chain of high-quality, medicinal cannabis flower in an under-supplied market.”

Caption: thegreenfund.com

According to LGP’s latest management changes, Morten Snede has been hired as a chief financial officer, while Tony Roberts has been designated as the EU territory’s general manager. Ms Solomon said, “Both men have a huge amount of industry expertise, having overseen the creation and development of significant medicinal cannabis businesses in their own right”. He added, “We are very excited that they have agreed to join [our] team and help realise our ambition of continuously improving patient access to cannabis medicines and being the world’s leading pure-play medicinal cannabis supplier.”

Latest news

Related news


Please enter your comment!
Please enter your name here